Showing results (41-50 of 10,490) with videos related to
Sort By:
Pageof 1,049
Appetite|April 23, 2022
People's intended serving behaviour at social vs. non-social mealsEmma V Long, Lenny R Vartanian, Kate Faasse, et al.Trends in Cancer|November 11, 2023
Affecting change as a clinical academicGeorgina V Long, Jennifer Durante, Matthew Browne, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced MelanomaFlorentia Dimitriou, Axel Hauschild, Janice M Mehnert, et al.The Lancet. Oncology|October 5, 2015
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trialsJean Jacques Grob, Georgina V Long, Dirk Schadendorf, et al.Critical Reviews in Oncology/Hematology|September 12, 2015
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaMatteo S Carlino, Georgina V Long, Richard F Kefford, et al.European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.Nature Reviews. Clinical Oncology|April 5, 2017
Targeted agents and immunotherapies: optimizing outcomes in melanomaJason J Luke, Keith T Flaherty, Antoni Ribas, et al.Pathology|March 30, 2016
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologistsHojabr Kakavand, James S Wilmott, Georgina V Long, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.Cancer Cell|February 9, 2021
Targeting the Microbiome to Overcome ResistanceRebecca C Simpson, Erin Shanahan, Richard A Scolyer, et al.Pageof 1,049